Arthur A. Levin - 12 Jun 2024 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
12 Jun 2024
Net transactions value
-$3,807,410
Form type
4
Filing time
14 Jun 2024, 19:03:48 UTC
Previous filing
07 Jun 2024
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Sale $1,402,628 -40,000 -16% $35.07 213,872 12 Jun 2024 By family trust F1, F2
transaction RNA Common Stock Sale $2,404,782 -60,000 -28% $40.08 153,872 13 Jun 2024 By family trust F1, F3
holding RNA Common Stock 14,830 12 Jun 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Award $0 +13,489 $0.000000 13,489 13 Jun 2024 Common Stock 13,489 $39.96 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on May 26, 2023 by the Reporting Person.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.89. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.